ROCKY MOUNTAIN CANCER CENTERS

No subgroup benefit observed in mosunetuzumab-axgb (Lunsumio) for untreated, low-tumor burden follicular lymphoma. Morningsun trial data: 95% objective response rate, 83.3% complete metabolic response. Common adverse events include injection-site reactions and cytokine release syndrome.

The celebration of treatment X's progression-free survival benefit may be misleading due to informative censoring, where higher toxicity leading to treatment discontinuation skews results in favor of X. Emphasis should shift to overall survival, sensitivity analyses, and time-to-treatment failure to accurately assess clinical benefit.

Mabel Mardones, MD, emphasizes the importance of diverse representation in clinical trials and medical field to build trust with patients. She advocates for better inclusion criteria in trials and dismantling biases among providers to ensure equitable access to effective treatments for HR+/HER2- breast cancer patients, regardless of socioeconomic status or geographic location.

Glenn Balasky emphasizes the need for experimentation and demonstration projects before fully integrating AI in cancer care to maintain doctor confidence and credibility.